Circulating tumor cells (CTCs) are vital components of liquid biopsies for diagnosis of
residual cancer, monitoring of therapy response, and prognosis of recurrence. Scientific …

Objective: This meta-analysis was designed to explore the association between the systemic
immune–inflammation index (SII) and the therapeutic effect of immune checkpoint inhibitors …

Cancer-related deaths are mainly caused by metastatic spread of tumor cells from the
primary lesion to distant sites via the blood circulation. Understanding the mechanisms of …

Cell cycle proteins that are often dysregulated in malignant cells, such as cyclin-dependent
kinase 4 (CDK4) and CDK6, have attracted considerable interest as potential targets for …

The adenoma-to-carcinoma progression in colon cancer is driven by a sequential
accumulation of genetic alterations at specific tumor suppressors and oncogenes. In …

Immune checkpoint inhibitors (ICIs), Ipilimumab, Nivolumab, Pembrolizumab and
Atezolizumab, have been applied in anti-tumor therapy and demonstrated exciting …

Background Treatment with immune checkpoint inhibitors (ICIs) has been associated with
an increased rate of cardiac events. There are limited data on the risk factors that predict …

Tissue factor (TF), an initiator of extrinsic coagulation pathway, is positively correlated with
venous thromboembolism (VTE) of tumor patients. Beyond thrombosis, TF plays a vital role …

Both platelets and the liver play important roles in the processes of coagulation and innate
immunity. Platelet responses at the site of an injury are rapid; their immediate activation and …

Abstract Platelet-rich-plasma (PRP) is an autologous human platelet concentrate extracted
from plasma. PRP has been investigated in order to be used in many fields, with emphasis …